| Primary | All-cause Mortality (Comparison 1) | All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated GLP-1 RA therapy with early SGLT2i add-on versus those who initiated GLP-1 RA therapy without early SGLT2i add-on (monotherapy). | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 1 (vs GLP-1 RA monotherapy). | | OG001 | GLP-1 RA Monotherapy (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | Major Adverse Cardiovascular Events (Comparison 1) | Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA monotherapy. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 1 (vs GLP-1 RA monotherapy). | | OG001 | GLP-1 RA Monotherapy (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1. |
|
| Secondary | Major Adverse Cardiovascular Events (Comparison 2) | Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA with usual care. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care). | | OG001 | GLP-1 RA With Usual Care (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of an SGLT2 inhibitor during the same window. This group represents the propensity score-matched GLP-1 RA with usual care comparator cohort for Comparison 2. |
|
| Secondary | Major Adverse Cardiovascular Events (Comparison 3) | Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i monotherapy. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 3 (vs SGLT2i monotherapy). | | OG001 | SGLT2i Monotherapy (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched SGLT2i monotherapy comparator cohort for Comparison 3. |
|
| Primary | All-cause Mortality (Comparison 2) | All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated GLP-1 RA therapy with early SGLT2i add-on versus those who initiated GLP-1 RA therapy with usual care (DPP-4 inhibitor, sulfonylurea, or insulin add-on). | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care). | | OG001 | GLP-1 RA With Usual Care (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of an SGLT2 inhibitor during the same window. This group represents the propensity score-matched GLP-1 RA with usual care comparator cohort for Comparison 2. |
|
| Primary | All-cause Mortality (Comparison 3) | All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated SGLT2i therapy with early GLP-1 RA add-on versus those who initiated SGLT2i therapy without early GLP-1 RA add-on (monotherapy). | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 3 (vs SGLT2i monotherapy). | | OG001 | SGLT2i Monotherapy (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched SGLT2i monotherapy comparator cohort for Comparison 3. |
|
| Primary | All-cause Mortality (Comparison 4) | All-cause mortality from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing adults with obesity, type 2 diabetes, CKM syndrome stage 2-3, and MASLD who initiated SGLT2i therapy with early GLP-1 RA add-on versus those who initiated SGLT2i therapy with usual care (DPP-4 inhibitor, sulfonylurea, or insulin add-on). | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 4 (vs SGLT2i with usual care). | | OG001 | SGLT2i With Usual Care (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of a GLP-1 receptor agonist during the same window. This group represents the propensity score-matched SGLT2i with usual care comparator cohort for Comparison 4. |
|
| Secondary | Major Adverse Cardiovascular Events (Comparison 4) | Composite of acute myocardial infarction, cardiac arrest, intracerebral or intracranial hemorrhage, and cerebral infarction from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i with usual care. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 4 (vs SGLT2i with usual care). | | OG001 | SGLT2i With Usual Care (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of a GLP-1 receptor agonist during the same window. This group represents the propensity score-matched SGLT2i with usual care comparator cohort for Comparison 4. |
|
| Secondary | Major Adverse Kidney Events (Comparison 1) | Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA monotherapy. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 1 (vs GLP-1 RA monotherapy). | | OG001 | GLP-1 RA Monotherapy (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1. |
|
| Secondary | Major Adverse Kidney Events (Comparison 2) | Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA with usual care. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care). | | OG001 | GLP-1 RA With Usual Care (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of an SGLT2 inhibitor during the same window. This group represents the propensity score-matched GLP-1 RA with usual care comparator cohort for Comparison 2. |
|
| Secondary | Major Adverse Kidney Events (Comparison 3) | Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i monotherapy. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 3 (vs SGLT2i monotherapy). | | OG001 | SGLT2i Monotherapy (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched SGLT2i monotherapy comparator cohort for Comparison 3. |
|
| Secondary | Major Adverse Kidney Events (Comparison 4) | Composite of end-stage kidney disease, dialysis dependence or initiation, kidney failure, and dialysis-related procedures from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i with usual care. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 4 (vs SGLT2i with usual care). | | OG001 | SGLT2i With Usual Care (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of a GLP-1 receptor agonist during the same window. This group represents the propensity score-matched SGLT2i with usual care comparator cohort for Comparison 4. |
|
| Secondary | Major Adverse Liver Outcomes (Comparison 1) | Composite of hepatic decompensation (ascites, hepatic encephalopathy, variceal bleeding, spontaneous bacterial peritonitis, hepatic failure, hepatorenal syndrome), hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 1, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA monotherapy. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 1 (vs GLP-1 RA monotherapy). | | OG001 | GLP-1 RA Monotherapy (Comparison 1) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and did not receive early add-on therapy with an SGLT2 inhibitor within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched GLP-1 RA monotherapy comparator cohort for Comparison 1. |
|
| Secondary | Major Adverse Liver Outcomes (Comparison 2) | Composite of hepatic decompensation, hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 2, comparing GLP-1 RA with early SGLT2i add-on versus GLP-1 RA with usual care. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | GLP-1 RA With SGLT2i Add-On (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added an SGLT2 inhibitor within 90 days after treatment initiation. This group represents the propensity score-matched GLP-1 RA + SGLT2i add-on cohort for Comparison 2 (vs GLP-1 RA with usual care). | | OG001 | GLP-1 RA With Usual Care (Comparison 2) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated GLP-1 receptor agonist therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of an SGLT2 inhibitor during the same window. This group represents the propensity score-matched GLP-1 RA with usual care comparator cohort for Comparison 2. |
|
| Secondary | Major Adverse Liver Outcomes (Comparison 3) | Composite of hepatic decompensation, hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 3, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i monotherapy. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 3 (vs SGLT2i monotherapy). | | OG001 | SGLT2i Monotherapy (Comparison 3) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and did not receive early add-on therapy with a GLP-1 receptor agonist within 90 days after treatment initiation. Participants could receive routine clinical care, including DPP-4 inhibitors, sulfonylureas, or insulin. This group represents the propensity score-matched SGLT2i monotherapy comparator cohort for Comparison 3. |
|
| Secondary | Major Adverse Liver Outcomes (Comparison 4) | Composite of hepatic decompensation, hepatocellular carcinoma, and liver transplantation from the 90-day landmark date through up to 60 months of follow-up in the propensity score-matched cohort for Comparison 4, comparing SGLT2i with early GLP-1 RA add-on versus SGLT2i with usual care. | Participants analyzed were members of the corresponding comparison-specific propensity score-matched cohort who were at risk at the start of the 60-month assessment window. Participants with the outcome before the assessment window were excluded. Therefore, the number analyzed may differ across outcomes. | Posted | | Number | | participants with event | | From 90 days after treatment initiation through up to 60 months of follow-up | | | | ID | Title | Description |
|---|
| OG000 | SGLT2i With GLP-1 RA Add-On (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a GLP-1 receptor agonist within 90 days after treatment initiation. This group represents the propensity score-matched SGLT2i + GLP-1 RA add-on cohort for Comparison 4 (vs SGLT2i with usual care). | | OG001 | SGLT2i With Usual Care (Comparison 4) | Adults with obesity, type 2 diabetes, cardiovascular-kidney-metabolic syndrome stage 2-3, and metabolic dysfunction-associated steatotic liver disease who initiated SGLT2 inhibitor therapy and added a DPP-4 inhibitor, sulfonylurea, or insulin within 90 days after treatment initiation, without initiation of a GLP-1 receptor agonist during the same window. This group represents the propensity score-matched SGLT2i with usual care comparator cohort for Comparison 4. |
|